Evaluation if physostigmin reduces symptoms in patients who has developed a delirium in Intensive care after a surgery

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 120

Inclusion Criteria

Patients of both genders aged > 18 years, < 85 years of ICU C1 after elective or emergency cardio surgery with or without extracorporeal circulation (heart–lung machine and/or extracorporeal membrane oxygenation), with suspected delirium. (May be suspected if a patient does not show adequate improvement of vigilance 24 h after adequate reduction or stop of sedative medicine)
- Patients (>18a, <85a) with CAM-ICU diagnosed delirium
- Patients of legal capacity and patients with appointed representative or informed consent of an independet consultant
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 60
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 60

Exclusion Criteria

- Asthma
- hypersensitivity against Physostigminsalicylat, Sodium metabisulfit, Nitrogen
- gangrene
- mechanical obstipation
- mechanical urinary retention
- Dystrophia myotonica
- Depolarization block after depolarising muscle relaxants
- Intoxications with „irreversibly acting cholinesterase inhibitors
- closed head trauma
- obstructions at gastro-intestinal tract and at urinary tract
- neurological diseases
- left ventricular ejection fraction < 40%
- Simultaneous Participation in other clinical trials or participation ind other clinical trials in the last 30 days
- untreated coronary heart disease
- wish to have chirldren, pregnancy or nursing
- patients with addicitve disorder in medical history

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Monocentre, randomized, double-blind, placebo-controlled, parallel-group in vivo study to evaluate the effects of the food supplement Hamaforton™ (Hamamelis virginiana L. Extract)

Not Applicable

IUF - Leibniz-Institut für umweltmed. Forschung GmbH

Updated 8/19/2024

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Phase 1

Actelion Pharmaceuticals Ltd

Updated 1/24/2022

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Actelion Pharmaceuticals Ltd

Updated 6/26/2012

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Actelion Pharmaceuticals Ltd

Updated 6/26/2012

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Actelion Pharmaceuticals Ltd

Updated 6/26/2012

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Phase 1

Actelion Pharmaceuticals Ltd

Updated 10/8/2021

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Actelion Pharmaceuticals Ltd

Updated 6/26/2012

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Actelion Pharmaceuticals Ltd

Updated 10/7/2014

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Phase 1

Actelion Pharmaceuticals Ltd

Updated 11/25/2019

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Actelion Pharmaceuticals Ltd

Updated 6/26/2012

Evaluation if physostigmin reduces symptoms in patients who has developed a delirium in Intensive care after a surgery

Recruitment & Eligibility

Study & Design

Related Trials

Monocentre, randomized, double-blind, placebo-controlled, parallel-group in vivo study to evaluate the effects of the food supplement Hamaforton™ (Hamamelis virginiana L. Extract)

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.

Clinical Trial Alerts

Clinical Trial Alerts